
|Articles|March 1, 2004
Etanercept shows safety, efficacy through five years
Washington -- A new study presented in poster form at the recent AAD meeting concludes that etanercept continues to post an excellent record for the treatment of rheumatoid arthritis. The drug maintains its safety profile and clinical efficacy for treatment durations of more than five years.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Karan Lal, DO, Shares Evolving Perspective on GLP-1 Agonists in Dermatology at SDPA Fall 2025
2
Dermatology Times Hosts 2025 Horizons in Advanced Practice Meeting
3
Nemolizumab Demonstrates Strong Efficacy in PN
4
Q&A: Treating Vitiligo in Difficult Sites Requires Patience and Precision
5



















